secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2023-10-11T23:59:59+00:00
Accession:  0001013762-23-003253
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital extension approved, ~$40.5M redeemed, up to $450k promissory note
--------------------------------------------------------------------------------

- Shareholders approved extension to July 11, 2024 with monthly $50k deposits; $50k deposited for first month.
- Approx 3.7M public shares redeemed for $40.5M ($10.92/share); public float reduced to ~4.54M shares.
- Issued convertible promissory note up to $450k to FutureTech Capital (initial $50k), convertible at $10/share upon business combination.
- Also approved founder share early conversion and removal of $5M net tangible asset redemption limitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/0001013762-23-003253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/ea186607-8k425_denalicap.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-003253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer